Viking Therapeutics stock reportedly surges 36% after weight-loss drug trial
Barron’s says Viking Therapeutics and Roche are developing obesity and diabetes drugs to challenge Eli Lilly and Novo Nordisk’s market duopoly.
TLDR
Barron’s reports that Viking Therapeutics shares surged 36% after a weight-loss drug trial. The outlet describes Viking and Roche as developing obesity and diabetes drugs aimed at challenging Eli Lilly and Novo Nordisk’s market duopoly.
Combined views
4.8K
1 Source, first seen 8d ago
6 likes3 comments2 reposts